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Abstract
Background: Intensivists and cardiothoracic surgeons are commonly worried about surgical site infections (SSIs)
due to increasing length of stay (LOS), costs and mortality. The antimicrobial prophylaxis is one of the most
important tools in the prevention of SSIs. The objective of this study was to investigate the relationship between
the timing of antimicrobial prophylaxis administration and the rate of SSIs.
Methods: A prospective cohort study was carried out over 1-year period in all consecutive adult patients
undergoing elective cardiac surgery. The population was stratified in patients whose antimicrobial prophylaxis
administration violated or not the vancomycin timing protocol (i.e., when the first skin incision was performed
before the end of vancomycin infusion). To compare SSI rates, the cohort was further stratified in patients at low
and high risk of developing SSIs.
Results: Over the study period, 1020 consecutive adult patients underwent cardiac surgery and according to study
inclusion criteria, 741 patients were prospectively enrolled. A total of 60 SSIs were identified for an overall infection
rate of 8.1%. Vancomycin prophylaxis timing protocol was violated in 305 (41%) out of 741 enrolled patients. SSIs
were observed in 3% of patients without violation of the antimicrobial prophylaxis protocol (13/436) compared
with 15.4% of patients with a violation of the timing protocol (47/305) (P < 0.0001). Patients at low risk with
protocol violation had a higher occurrence of SSIs (P = 0.004) and mortality (P = 0.03) versus patients at low risk
without protocol violation. Similarly, patients at high risk with protocol violation had a higher occurrence of SSIs
(P < 0.001) and mortality (P < 0.001) versus patients at high risk without protocol violation. The logistic regression
analysis showed that internal mammary artery use (P = 0.025), surgical time (P < 0.001), intensive care unit (ICU) LOS
(P = 0.002), high risk of developing SSIs (P < 0.001) and protocol violation (P < 0.001) were risk factors for SSI
occurrence as well as age (P = 0.003), logistic EuroSCORE (P < 0.001), ICU LOS (P < 0.001), mechanical ventilation time
(P < 0.001) and protocol violation (P < 0.001) were risk factors for mortality.
Conclusions: This study showed that violation of the timing of prophylactic vancomycin administration
significantly increased the probability of SSIs and mortality from infectious cause in cardiac surgery patients.
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Background
The incidence of surgical site infections (SSIs) after
cardiac surgery ranges differently according to the type
of wound infection; specifically, superficial wound infec-
tion occurs in 2 to 20% of patients and deep sternal
wound infection occurs in 0.25 to 5% [1–6].
Risk factors that have been linked to SSIs include fea-
tures in the host such as advanced age, the presence of
liver or lung dysfunction, cancer, diabetes mellitus and
over- or undernutrition [7, 8]. Similarly, several oper-
ation characteristics can influence the risk of infection
in cardiac surgery: skin antisepsis; length of operation;
surgical technique; coronary artery bypass graft
(CABG) surgery involving the use of a saphenous vein
autograft that can carry bacteria from the harvest site
deep into the cardiac operative site; use of the internal
mammary artery (IMA) that deprives the sternum of
blood supply; the use of prosthetic intracardiac or
aortic implants; cardiopulmonary bypass or systemic
cooling for myocardial protection; and invasive devices
remaining after surgery (chest drains, pacing wires and
intravenous catheters) [1, 8, 9]. Recent reports focused on
an increasing number of infections caused by resistant
Gram-positive pathogens, such as methicillin-resistant
Staphylococcus aureus (MRSA) and coagulase-negative
staphylococcus [4, 5, 10]. Compared with methicillin-
sensitive Staphylococcus aureus mediastinitis, MRSA med-
iastinitis has up to an 11-fold increased mortality rate [5].
In patients undergoing cardiac surgery, an SSI is associ-
ated with increased morbidity, prolonged length of stay and
increased costs with an in-hospital mortality rate of
10–20% [1, 6, 11]. Thus, many preventive measures
were suggested as effective for reducing the incidence
of SSIs, such as preoperative screening for carriage of
multiresistant organisms (e.g., MRSA), antimicrobial
prophylaxis, preoperative skin preparation, accurate
surgical technique, postoperative glycemic control and
wound management [9, 12]. Antimicrobial intravenous
prophylaxis is routinely administered to patients
undergoing cardiac surgery because the benefits of
preoperative antibiotic administration in these patients
have been clearly demonstrated in placebo-controlled
studies [13]. However, the debate over choice, dose,
duration and timing of antimicrobial prophylaxis
protocol is still all the rage [14].
Seminal literature demonstrated that antimicrobial
prophylaxis administered too late or too early reduced
the efficacy of the antibiotic and may increase the risk of
SSI [7]. The definite timing of administration of the first
antibiotic dose has not been assessed in randomized
controlled trials; however, there is a strong rationale
supporting the need for the timely administration of pre-
operative antimicrobial prophylaxis [7, 11, 15]. Indeed,
the timing of the administration of the prophylactic
antibiotic is still an important issue for the cardiac sur-
gical community [16–19], because despite the existence
of published guidelines and locally agreed protocols for
the antimicrobial prophylaxis administration, often
there is a gap between what is recommended and what
is practiced [15, 20].
The primary objective of this study was to investigate
the relationship between the timing of antimicrobial
prophylaxis administration —with respect to surgical in-
cision time— and the rate of SSIs, comparing cardiac
surgery patients at low and high risk of infection. This
objective was related to a specific exploratory mandate
received from our Hospital Infection Control Committee
to evaluate our policy of antimicrobial prophylaxis in
cardiac surgery.
Methods
Study design
A single-centre prospective cohort study was carried out
in the Department of Cardiovascular Surgery of a 1200-
bed tertiary care university hospital (S. Giovanni Battista
Hospital). Over 1-year period, all consecutive adult
patients undergoing cardiac surgery were assessed for
eligibility. The exclusion criteria were renal dysfunction
(on dialysis or creatinine clearance ≤30 mL/min, esti-
mated by the Cockcroft-Gault formula); infectious dis-
eases that required antibiotic therapy in the previous
2 weeks; heart and lung transplant surgery; solid or
hematologic tumours as well as chemotherapy or radi-
ation therapy in the previous 6 months; preoperative
stay in intensive care unit (ICU) more than 24 h; allergy
to cefazolin or vancomycin; and emergency operations.
The study protocol was reviewed and approved by our
Institutional Ethics Committee (No. 0078553) and pa-
tients provided written informed consent before their
enrolment. The work was conducted in compliance with
Institutional Review Board/Human Subjects Research
Committee requirements.
Our protocol of antimicrobial prophylaxis was a single
1000 mg cefazolin dose, diluted in 20 mL 0.9% NaCl
solution, initiated 30 to 60 min before surgery and ad-
ministered as a slow intravenous bolus; plus a single
1000 mg vancomycin dose, diluted in 100 mL 0.9% NaCl
solution, started within 2 h before surgery and adminis-
tered over 60 min intravenously infusion to prevent the
release of histamine. A further three doses of cefazolin
1000 mg at 8-h intervals were given postoperatively,
while no further vancomycin doses were administrated
postoperatively. Since 2005, our protocol provides the
choice to combine cefazolin with vancomycin for anti-
microbial prophylaxis in patients undergoing cardiac
surgery. The rationale for using vancomycin was an in-
creased prevalence of MRSA infections, which exceeded
60% hospital-wide and isolates identified in cardiac
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surgery patients with SSIs. Antimicrobial prophylaxis is
started in the preoperative holding area. Vancomycin
protocol and timing of administration were chosen
based upon recommendations of our Hospital Infection
Control Committee according to the Sanford Guide [21]
and the Society of Thoracic Surgeons Guidelines [16].
The study population was stratified in patients whose
antimicrobial prophylaxis administration violated or not
our vancomycin timing protocol. Antimicrobial prophy-
laxis timing protocol was considered as violated when the
first surgical skin incision was performed before the end
of the vancomycin infusion. A healthcare provider (i.e.,
physician, nurse or cardiovascular technician) was re-
quired to document the exact time the antibiotic infusion
was started, as well anaesthesiologists or cardiac surgeons
who recorded the exact time the first skin incision.
To compare SSI rates adequately, the cohort was
further stratified in patients at low and high risk of
developing SSIs according to the literature [1, 8, 10].
Specifically, patients were included in the high risk
group in case of: (i) chronic liver disease (classified as
Child-Pugh class B and C); (ii) insulin-dependent dia-
betes; (iii) body mass index (BMI) <17 or >40 kg/m2;
(iv) steroid or other immunosuppressive drug use; (v)
chronic obstructive pulmonary disease; and (vi) extracar-
diac arteriopathy (i.e., claudication, carotid occlusion or
>50% stenosis, amputation for arterial disease and previ-
ous or planned intervention on the abdominal aorta, limb
arteries or carotids). Thus, cardiac surgery patients were
assigned to four groups according to SSI risk factors and
violation of the timing of antimicrobial prophylaxis proto-
col administration as follows: (i) low risk patients without
protocol violation; (ii) low risk patients with protocol
violation; (iii) high risk patients without protocol violation;
and (iv) high risk patients with protocol violation.
According to Centers for Disease Control and Prevention
(CDC) guidelines [8], the definition of an SSI requires that
one of the following criteria be met: (i) superficial (infection
above the sternum with no bone involvement); (ii) deep
(infection involving the sternum and organ/space such as
mediastinitis); and (iii) leg donor site infections. Patients
with SSI must have positive culture results of surgical sites
or drainage from the mediastinal area or evidence of infec-
tion during surgical re-exploration or fever, sternal instabil-
ity and positive blood culture results [8]. Other infectious
complications were defined as bloodstream infection (BSI),
lower respiratory tract infection (LRTI) and urinary tract
infection (UTI) according to CDC guidelines. Perioperative
management and skin preparation were standardized in
our Department according to CDC guidelines. According
to the literature, patients were followed up for 30 days after
the surgical procedure [18, 19]. Mortality was defined as
death during hospitalization or within 30 days after surgery
from infectious cause.
Statistical analysis
The patients’ characteristics were analysed by the Fisher’s
exact test for categorical variables, while by the
Fig. 1 Study design. aDialysis or creatinine clearance ≤30 mL/min. bInfectious diseases that required antibiotic therapy in the previous 2 weeks.
cPatients with solid or hematologic tumours, as well as patients underwent chemotherapy or radiation therapy in the previous 6 months.
dPreoperative stay in the intensive care unit (ICU) for more than 24 h. ePatients were considered at high risk of developing surgical site infections in
case of: chronic liver disease (classified as Child-Pugh class B and C); insulin-dependent diabetes; body mass index <17 or >40 kg/m2; steroid or other
immunosuppressive drug use; chronic obstructive pulmonary disease; and extracardiac arteriopathy (i.e., claudication, carotid occlusion or >50%
stenosis, amputation for arterial disease and previous or planned intervention on the abdominal aorta, limb arteries or carotids). fViolation of
antimicrobial prophylaxis timing protocol
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Mann–Whitney test for continuous ones; all results
for the latter were expressed as the median (range).
Two different independent series of univariate/multi-
variate binary logistic regression models were used to
estimate the odds of SSI occurrence and mortality
within 30 days after surgery (dependent variables),
evaluating as their risk factors: gender, IMA use, high
risk of developing SSIs and protocol violation (independ-
ent categorical variables) as well as age, BMI, surgical time,
logistic EuroSCORE, mechanical ventilation time and ICU
length of stay (LOS) (independent continuous variables).
All reported P values were obtained by the two-sided exact
method, at the conventional 5% significance level. Data
were analysed by R 3.3.2 (R Foundation for Statistical
Computing, Vienna-A, http://www.R-project.org).
Results
Over the study period, 1020 consecutive adult patients
underwent cardiac surgery. According to study inclusion
criteria, 741 patients were prospectively enrolled, while
279 patients were excluded (Fig. 1). Main patients’ char-
acteristics are reported in Table 1. According to variables
considered as risk factors for infectious complications,
402 patients were considered at low risk of developing
SSIs and 339 were considered at high risk. Of the 741
patients included in the study, antimicrobial prophylaxis
timing protocol was violated in 305 patients (41.2%);
specifically, in these patients the skin incision was per-
formed before the end of the vancomycin infusion. No
patients had vancomycin infusion more than 120 min
prior to skin incision. No violation regarding cefazolin
administration was observed.
Table 2 shows infectious complications. SSIs were
8.1%: two-thirds were superficial wound infections of the
chest, deep infections were 25% and few were at a donor
site. SSIs were observed in 3% of patients without viola-
tion of the antimicrobial prophylaxis protocol (13/436)
compared with 15.4% of patients with a violation of the
Table 1 Patients’ characteristics
Low risk (n = 402) High risk (n = 339)
Without protocol
violation
With protocol
violation
P Without protocol
violation
With protocol
violation
P
n 236 166 200 139
Age, median (range) 70 (25–86) 70 (34–84) 0.51 71 (37–88) 71 (44–88) 0.50
Male gender, n (%) 149 (63) 100 (60.2) 0.63 124 (62) 74 (53.2) 0.13
BMI, kg/m2, median (range) 26 (18–40) 26 (18–39) 0.81 28 (17–43) 28 (17–41) 0.84
Diabetes, n (%) 46 (19)a 27 (16.3)a 0.41 50 (25)b 45 (32.4)b 0.17
COPD, n (%) 0 0 ─ 24 (12) 13 (9.3) 0.55
Hypertension, n (%) 151 (64) 108 (65.1) 0.91 132 (66) 99 (71.2) 0.37
Smoke, n (%) 28 (12) 30 (18.1) 0.11 52 (26) 48 (34.5) 0.12
Surgical time, min, median (range) 249 (119–593) 255 (132–495) 0.49 247 (140–442) 243 (152–430) 0.60
Surgical procedure, n (%) 0.08 0.11
CABG 72 (30.5) 58 (34.9) 70 (35) 53 (38.1)
Valve 113 (47.9) 59 (35.5) 52 (26) 24 (17.3)
CABG + Valve 34 (14.4) 30 (18.1) 24 (12) 12 (8.6)
Otherc 17 (7.2) 19 (11.5) 54 (27) 50 (36)
Off-pump CABG, n (%) 21 (8.9) 8 (4.8) 0.17 11 (5.5) 9 (6.5) 0.89
Left IMA, n (%) 53 (22.4) 40 (24.1) 0.79 44 (22) 33 (23.7) 0.81
Both IMA, n (%) 17 (7.2) 8 (4.8) 0.44 13 (6.5) 9 (6.5) >0.99
EuroSCORE additive, median (range) 5 (1–6) 5 (1–6) 0.80 8 (1–16) 8 (1–14) 0.72
EuroSCORE logistic, median (range) 4.8 (1–7.74) 4.6 (1–7.21) 0.41 9.7 (1–44.45) 9.9 (1–61.86) 0.37
Mechanical ventilation, h, median (range) 7 (2–912) 8 (6–415) 0.31 9 (7–816) 9 (8–711) 0.49
ICU stay, d, median (range) 1 (1–24) 1 (1–38) 0.52 1 (1–33) 1 (1–45) 0.30
RBC transfusions, n, median (range) 2 (0–9) 2 (0–6) 0.71 3 (0–11) 2 (0–10) 0.61
BMI body mass index, COPD chronic obstructive pulmonary disease, CABG coronary artery bypass grafting, IMA internal mammary artery, EuroSCORE European
System for Cardiac Operative Risk Evaluation, h hours, ICU intensive care unit, d days, RBC red blood cell
aNon-insulin-dependent diabetes
bInsulin-dependent diabetes
cAortic, atrial or ventricular septal defect repair, and congenital surgery
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timing protocol (47/305) (P < 0.0001). Patients at low
risk with protocol violation had a higher occurrence of
SSIs (P = 0.004), BSIs (P = 0.01) and mortality (P = 0.03)
versus patients at low risk without protocol violation.
Patients at high risk with protocol violation had a higher
occurrence of SSIs (P < 0.001), BSIs (P < 0.001), LRTIs
(P < 0.001), UTIs (P < 0.001) and mortality (P < 0.001)
versus patients at high risk without protocol violation.
Patients at high risk without violation of the antimicro-
bial prophylaxis protocol had a higher occurrence of
SSIs (P = 0.0 4), BSIs (P = 0.04), LRTIs (P < 0.001) and
mortality (P = 0.04) versus patients at low risk without
protocol violation. Patients at high risk with protocol
violation had a higher occurrence of SSIs (P < 0.001),
BSIs (P < 0.001), LRTIs (P < 0.001), UTIs (P < 0.001) and
mortality (P = 0.003) versus patients at low risk with
protocol violation.
The logistic regression analysis showed that IMA
use (P = 0.025), surgical time (P < 0.001), ICU LOS
(P = 0.002), high risk of developing SSIs (P < 0.001)
and protocol violation (P < 0.001) were risk factors
for SSI occurrence (Table 3) as well as age (P = 0.003),
logistic EuroSCORE (P < 0.001), ICU LOS (P < 0.001),
mechanical ventilation time (P < 0.001) and protocol viola-
tion (P < 0.001) were risk factors for mortality (Table 4).
Ninety-two pathogens isolated in 60 SSIs are shown in
Table 5. Specifically, Gram-positive, Gram-negative and
fungi were isolated in 48, 40 and 12%, respectively. Path-
ogens isolated in SSIs by groups are depicted in Table 6.
Methicillin-resistant Staphylococci (aureus, coagulase-
Table 2 Infectious complications
Low risk (n = 402) High risk (n = 339)
Without protocol violation With protocol violation Without protocol violation With protocol violation Total
N 236 166 200 139 741
SSI, n (%) 3 (1.3) 12 (7.2)a 10 (5)b 35 (25.2)c,d 60 (8.1)
Superficial, n 1 8 4 25 38 (63.3)
Deep, n 2 2 5 6 15 (25)
Donor site, n 0 2 1 4 7 (11.7)
BSI, n (%) 2 (0.8) 8 (4.8)e 12 (6)b 49 (35.2)c,d 71 (9.6)
LRTI, n (%) 7 (3) 8 (4.8) 25 (12.5)f 39 (23.1)c,d 79 (10.7)
UTI, n (%) 0 1 (0.6) 3 (1.5) 15 (10.8)c,d 19 (2.6)
Mortality§, n (%) 3 (1.3) 8 (4.8)g 9 (4.5)b 20 (14.4)c,h 40 (5.4)
SSI surgical site infection, BSI bloodstream infection, LRTI lower respiratory trait infection, UTI urinary trait infection
§During hospitalization or within 30 days after surgery from infectious cause
aP = 0.004 versus low risk group without protocol violation
bP = 0.04 versus low risk group without protocol violation
cP < 0.001 versus high risk group without protocol violation
dP < 0.001 versus low risk group with protocol violation
eP = 0.01 versus low risk group without protocol violation
fP < 0.001 versus low risk group without protocol violation
gP = 0.03 versus low risk group without protocol violation
hP = 0.003 versus low risk group with protocol violation
Table 3 Risk factors for surgical site infections (SSIs)
Logistic regression
Univariate models
Logistic regression
Multivariate model
Odds ratio 95% CI P Odds ratio 95% CI P
Body mass index 1.07 1.02-1.13 0.007 1.01 0.94-1.08 0.781
Internal mammary artery use 1.85 1.08-3.17 0.026 2.11 1.10-4.04 0.025
Surgical time 1.01 1.01-1.02 <0.001 1.01 1.01-1.02 <0.001
Intensive care unit LOS 1.12 1.09-1.16 <0.001 1.06 1.02-1.10 0.002
High riska 3.95 2.16-7.22 <0.001 4.70 2.32-9.53 <0.001
Protocol violationb 5.93 3.15-11.17 <0.001 7.03 3.41-14.52 <0.001
CI Confidence interval, LOS length of stay
aHigh risk of developing SSIs according to the literature [1, 8, 10]; in case of: (i) chronic liver disease (classified as Child-Pugh class B and C); (ii) insulin-dependent
diabetes; (iii) body mass index <17 or >40 kg/m2; (iv) steroid or other immunosuppressive drug use; (v) chronic obstructive pulmonary disease; and (vi)
extracardiac arteriopathy (i.e.,claudication, carotid occlusion or >50% stenosis, amputation for arterial disease and previous or planned intervention on the
abdominal aorta, limb arteries or carotids)
bAntimicrobial prophylaxis timing protocol was considered as violated when the first surgical skin incision was performed before the end of the
vancomycin infusion
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negative and hominis) accounted for 28% of pathogens.
When we studied methicillin-resistance or vancomycin
susceptibility of Gram-positive isolates according to the
timing of antimicrobial prophylaxis none of the differ-
ences between groups in the rate of such resistances
reached statistical significance. No clusters of any
specific pathogen were noted during the study period.
Discussion
In this study, cardiac surgery population was divided in
patients at high risk of developing infections because of
well-known risk factors and patients at low risk. As ex-
pected, patients at high risk (i.e., patients with severe co-
morbidities, immunosuppressive therapy, severe obesity
or malnutrition) had a significant higher occurrence of
SSIs as well as of BSIs, LRTIs and mortality compared
with patients at low risk, independently of violation of
the antimicrobial prophylaxis protocol. This finding re-
flects a population of patients who were more severely
ill and therefore at higher risk for postoperative infec-
tious complications.
The Society of Thoracic Surgeons Practice Guidelines
on antibiotic prophylaxis in cardiac surgery recom-
mended that in the setting of the institutional presence
of a ‘high incidence’ of MRSA, it would be reasonable to
combine a β-lactam (cefazolin) with a glycopeptide
(vancomycin) for prophylaxis (Class IIB recommenda-
tion, Level of Evidence C) [16]. Optimal dosage regimens
of vancomycin and protocol of administration still re-
main controversial [16, 22]. The Society of Thoracic Sur-
geons Guidelines mentioned that any of the following
doses and durations may be used: 1000 mg, 1500 mg, or
15 mg/kg; and 24 h versus 48 h or 1 dose versus 2 doses
[16, 22]. Specifically, guidelines for appropriate dosing of
prophylactic antibiotics stated that ‘In patients for whom
vancomycin is an appropriate prophylactic antibiotic for
cardiac surgery, a dose of 1 to 1.5 g or a weight-adjusted
dose of 15 mg/kg administered intravenously slowly over
1 h, with completion within 1 h of the skin incision, is
recommended’ (Class I, Level of Evidence A) [16]. Simi-
larly, the 2011 American College of Cardiology/Ameri-
can Heart Association guideline for CABG surgery
recommended that ‘Antibiotic prophylaxis should be
initiated 30 to 60 min before surgery, usually at the time
of anaesthetic induction, except for vancomycin, which
should be started 2 h before surgery and infused slowly’
[6]. Finally, the Scottish Intercollegiate Guidelines
Network, updated April 2014, stated that ‘Vancomycin
should be given by intravenous infusion starting 90 min
prior to skin incision’ (Class B recommendation) [9].
Several studies investigated the association between
measure(s) applied for reducing the rate of SSIs and
their occurrence [23, 24]. Our study focused on the
timing of antimicrobial prophylaxis; specifically, on the
relationship between the first skin incision and the end
of vancomycin infusion. We found that the initial surgi-
cal incision was performed before the vancomycin infu-
sion had been completed in nearly 40% of patients.
Generally, the reason for the violation of the antimicro-
bial prophylaxis protocol was due to our policy to start
antimicrobial prophylaxis in the preoperative holding
area under supervision of anaesthesiologists. This policy
was adopted in our Cardiovascular Surgery Unit follow-
ing the occurrence of some relevant adverse drug reac-
tions due to vancomycin administration (i.e., mainly
hypotension; occasionally, red man syndrome) [23, 24].
Differently, in the Garey’s study [25] cardiac surgery
patients were assigned to five groups on the basis of the
Table 4 Risk factors for mortalitya
Logistic regression
Univariate models
Logistic regression
Multivariate model
Odds ratio 95% CI P Odds ratio 95% CI P
Age 1.13 1.07-1.19 <0.001 1.15 1.05-1.26 0.003
EuroSCORE logistic 1.24 1.17-1.31 <0.001 1.21 1.11-1.33 <0.001
Intensive care unit LOS 1.25 1.20-1.31 <0.001 1.14 1.07-1.21 <0.001
Mechanical ventilation time 1.34 1.24-1.45 <0.001 1.18 1.08-1.29 <0.001
Protocol violationb 3.57 1.79-7.14 <0.001 10.16 2.48-41.58 <0.001
CI Confidence interval, LOS length of stay
aDuring hospitalization or within 30 days after surgery from infectious cause
bAntimicrobial prophylaxis timing protocol was considered as violated when the first surgical skin incision was performed before the end of the
vancomycin infusion
Table 5 Pathogens isolated in 60 surgical site infections
Pathogens, n 92
Gram-positive organisms, n (%) 44 (48)
Staphylococcus aureus, n 23
Coagulase-negative staphylococci, n 11
Enterococcus spp, n 9
Streptococci, n 1
Gram-negative organisms, n (%) 37 (40)
Fungi, n (%) 11 (12)
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relation between the start time of the vancomycin infusion
and the time of the initial surgical incision. In this study,
antibiotic prophylaxis was started in the preoperative
holding area only for the first surgical case of the day and
in admission unit for all subsequent cases immediately
prior to transferring the patient to the preoperative hold-
ing area. These Authors reported that of the 2048 patients
in the study, 0.7% received vancomycin 0–15 min before
incision, 8.6% 16–60 min before incision, 43.4% 61–
120 min before incision, 34.2% 121–180 min before
incision and 13.1% >180 min before incision.
The relationship between the timing of antimicrobial
prophylaxis and the occurrence of SSIs has been studied
with conflicting results. The Surgical Care Improvement
Project measure assesses compliance for antimicrobial
prophylaxis administration initiated within 60 min (or
120 min for vancomycin) prior to surgical incision [11].
The choice of the preincision 60-min window for anti-
microbial prophylaxis was based on two types of
evidence: pharmacokinetics of the antibiotics and one
large cohort study analyzing the association between
timing of antibiotic administration and SSIs in several
types of surgical procedures [11].
However, following studies investigating this relationship
did not clearly demonstrate the superiority of the 60-min
window [17–20]; in particular, some studies showed lower
risk of SSI with shorter times between antibiotic adminis-
tration and skin incision. Garey et al. reported that SSI
developed in 26.7% of cardiac surgery patients who received
vancomycin 0–15 min before incision, 3.4% of patients
between 16 and 60 min before incision, 7.7% of patients
between 61 and 120 min before incision, 6.9% of patients
between 121 and 180 min before incision and 7.8% of pa-
tients >180 min before incision [25]. Steinberg et al. in an
observational study (43.6% were cardiac patients) found a
trend toward lower risk of SSI occurring when antimicro-
bial prophylaxis with vancomycin or cephalosporins were
given within 60 and 30 min prior to incision, respectively
[18]. Hawn et al. in a retrospective study in noncardiac
surgery patients found that the SSI risk was not significantly
associated with prophylactic antibiotic timing [19].
SSIs are still among the most severe complications in
cardiac surgery patients. The overall SSI rate observed in
our study was 8.1%, which was similar or lower to that
previously reported [1–3]. The main finding of our study
was that violation of the timing of vancomycin prophy-
laxis protocol was a significant risk factor for develop-
ment of SSI in patients undergoing cardiac surgery.
Specifically, when the first surgical skin incision was
performed before the end of the vancomycin infusion,
we observed a 5-fold increased rate of SSIs both in low
and high risk patients.
Nosocomial infections occur in 10 to 20% of cardiac
surgery patients [6]; however, while SSIs incur significant
morbidity and costs but rarely lead to death, conversely,
postoperative LRTI, BSI and endocarditis are more fre-
quently correlated with mortality [15]. In our study, we
also found a consistent relationship between violation of
vancomycin prophylaxis timing protocol and rates of
postoperative infectious complications as well as mortal-
ity from infectious cause. Specifically, BSIs and mortality
were increased 6-fold and more than 3-fold, respectively
both in low and high risk patients. Moreover, LRTIs and
UTIs were increased 2-fold and 7-fold, respectively in
high risk patients. Also for mortality, violation of the tim-
ing of vancomycin prophylaxis protocol was a significant
risk factor.
Actually, before starting this study we did not suspect
that the timing of vancomycin prophylaxis administration
was being violated at this rate as well as that this violation
Table 6 Pathogens isolated in surgical site infections by groups
Low risk (n = 402) High risk (n = 339) Total
Without protocol violation With protocol violation Without protocol violation With protocol violation
SSI, n (%) 3/236 (1.3) 12/166 (7.2) 10/200 (5) 35/139 (25.2) 60/741 (8.1)
Pathogen, n 3 24 12 53 92
Gram-positive, n (%) 1 (33) 11 (46) 5 (42) 27 (51) 44 (48)
Methicillin-sensitive, n 1 3 2 12 18
Methicillin-resistant, n 0 8 3 15 26
Vancomycin susceptibility
MIC ≤1, n 1 9 3 17 30
MIC =2, n 0 2 1 9 12
MIC ≥4, n 0 0 1 1 2
Gram-negative, n (%) 1 (33) 12 (50) 4 (33) 20 (38) 37 (40)
Fungi, n (%) 1 (33) 1 (4) 3 (25) 6 (11) 11 (12)
Multiple pathogens were identified in some patients; therefore, total pathogens identified do not add up to the total number of SSIs. SSI Surgical Site Infection,
MIC minimum inhibitory concentration
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was associated with a significantly increased rate of SSIs,
postoperative infectious complications and mortality from
infectious cause. However, the overall SSI rate and mortal-
ity observed in our study were similar or lower to those
previously reported in other studies in cardiac surgery
patients [1–6].
Policies and practices aimed at reducing the risk of
SSIs include performing surveillance for SSIs as well
as measuring and providing feedback to healthcare
providers on the rates of compliance with process
measures, including antimicrobial prophylaxis [7, 12].
This study let us to discover that the violation of the
protocol was due to the start of antimicrobial prophy-
laxis in the preoperative holding area. Indeed, the
information obtained in this study was reported to
our healthcare providers and has altered practice pat-
terns for avoiding the persistent risk of violation of
prophylactic vancomycin administration timing.
Strengths and limitations of the study
If compared with previous studies, our study has
some relevant features: (1) it was a prospective study;
(2) data were collected through a clinical study and
not from a database or registry; (3) antibiotic timing
data were collected in ‘real-time’ in the operating
room and not from the patient chart; (4) only cardiac
surgery patients were enrolled; (5) all patients re-
ceived the same prophylactic administration of antibi-
otics; (6) the rate of BSIs, LRTIs, UTIs and mortality
from infectious cause were also investigated; (7) it
was concluded in only 12 months and (8) no patient
was lost to follow-up. Moreover, to the best of our
knowledge, this is the first study investigating the re-
lationship between the rate of SSIs in cardiac surgery
patients and the presence or absence of violation of
the timing of antimicrobial prophylaxis administra-
tion, comparing patients at low and high risk of
infections.
The study presented several limitations. First, it was a
single-centre study. Second, neither a calculation was
made on the number of subjects required nor an interim
analysis was conducted since the study was designed by
our statistician to be continuous over one year. Specific-
ally, the duration of a year was necessary to enrol an
adequate number of patients (i.e., 741) to obtain statisti-
cally significant differences among the groups. As a
matter of fact, the earlier studies enrolled a number of
patients ranging among 2048 and 4472 [18, 25].
Moreover, being an observational study, there was no
randomization of patients to the two groups (with and
without protocol violation), although the characteristics
of patients in the two groups turned out not to be statis-
tically different. Finally, in the study period patients were
not screened for S. aureus colonization prior to surgery.
Conclusions
The variability in antimicrobial prophylaxis timing
significance among results reported in the literature
suggests that the association between timing and SSIs
is greatly related to the surgical population, the anti-
biotic(s) and the timing intervals investigated.
Despite some limitations, our study showed that viola-
tion of the timing of prophylactic vancomycin adminis-
tration significantly increased the probability of SSIs and
mortality from infectious cause in patients undergoing
cardiac surgery.
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